



SKiN-HUID cordially invites you to:

Progress in Personalised Medicine Developing a novel biopharmaceutical, from bench to production

May 16

Brightlands Chemelot Campus, Geleen (NL)
Registration: www.lifeteczone.nl/nl/agenda

About the event

A major challenge in the development of biopharmaceuticals is achieving clinical grade products for clinical evaluation. Under the framework of the Interreg V Netherlands and Flanders -project SKiN-HUID, Basic Pharma and MosaMedix, Universities of Maastricht, Antwerp and the Flemish Institute for Biotechnology (VIB) at the KU Leuven joined forces.

SKiN-HUID develops a novel treatment of skin cancer that combines administration of a biopharmaceutical medicine targeting cancer cells and application of electrical and hyperthermal stimulation of the cancer that enhances the efficacy of the biopharmaceutical medicine.

Within SKiN-HUID the consortium aims to overcome the major hurdle of bringing a novel biopharmaceutical product to the clinic: the GMP-production of clinical grade biopharmaceutical medicine for the first phase of clinical studies. Basic Pharma set up a novel pilot plant for the GMP-production of biopharmaceutical medicines. This facility forms an essential part of the value chain linking preclinical and clinical evaluation of the efficacy of biopharmaceutical medicines.

Collaboration between University and Industry, access to finance, infrastructure and regulatory insight is paramount in mastering this challenge. We cordially invite you to join our mission in accelerating personalised medicine innovations.

Program May 16

- 12.00 Lunch
- 13.00 Welcome
- 13.10 Brightlands, a knowledge and technology hub to facilitate collaboration between Industry and University.
Bert Kip, Brightlands Chemelot Campus
- 13.20 SKiN-HUID, a Euregional collaboration between Industry and Universities to improve the treatment of skin cancer.
Chris Reutelingsperger, Maastricht University
- 13.35 Melanoma Patient-Derived Tumor Xenografts in mice as preclinical models to understand carcinogenesis and to predict efficacy of novel anticancer drugs.
Michael Dewaele, VIB Center for Cancer Biology KULeuven
- 13.55 The role of pathology in translating experimental treatments from the preclinic to clinical application.
John-Paul Bogers, University of Antwerp
- 14.20 GMP-production of biologicals for the first-in-man clinical study. *Ralph Bosmans, Basic Pharma Technologies B.V.*
- 14.45 Regulatory aspects during (early) development of biopharmaceuticals
Jacques Havermans, Interdos Pharma B.V.
- 15.10 SME pitches: Novel technologies in personalised medicine
Matisse Pharmaceuticals B.V.- Brightlands Campus - Peter Ekhart
Noviocell B.V. – Pivot Park Oss - Juliette van den Dolder
CiMaas B.V. – Brightlands Campus – Wilfred Germeraad
- 16.00- 17.30 Networking

Registration

The meeting is especially of interest to companies active in biotechnology, pharmaceuticals and medical devices, and start-up support.

Register now for the event free of charge (registration mandatory) via:

www.lifeteczone.nl/nl/agenda/mei2019

[Register Now](#)